Immune Support, PMDD & Retatrutide Metabolic Flexibility #health #peptides

About this video

In this office-hours answer Seeds reframes a question linking immune concerns, Sjogren’s syndrome, and mould exposure to whether a fibrin-targeting enzyme treats mould or biofilm. He argues that is the wrong question, and urges clinicians to think in phenotypes and early drivers instead: is a fibrin-directed intervention safe, does it improve antimicrobial penetration, microcirculation, or inflammatory load? Seeds says he is more focused on micro-inflammation and micro-clotting than on proven biofilm reduction, which he says no one can guarantee, and he discusses pentosan polysulfate as an agent he claims has helped microcirculation through anticoagulant and anti-inflammatory properties. The available transcript covers only this first question, despite broader topics in the title.

Key takeaways

• Reframe ‘does it treat X’ into safety, mechanism, and phenotype questions, Seeds advises
• Microcirculation and inflammatory load are presented as more actionable targets than unproven biofilm claims
• No one can guarantee biofilm reduction, Seeds cautions — avoid overclaiming
• Improving the tissue environment may matter more than targeting a single structure

Episode details: published July 6, 2026 · 267 views · 3:00 long. Summary written by Self Growth Videos from the episode itself. The peptide and cellular-medicine concepts described are Dr. William Seeds’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: the SSRP Institute sells clinician certification in peptide therapy.

← Previous: Ep.10 - AMA with Dr. Seeds: Your Questions Answered · Next: GLP-1s for Menopause (Ep.67) →

All Dr. William Seeds videos · Dr. William Seeds profile · SSRP Institute (official site)